Neuland Lab Ltd.

NEULANDLAB NSE Healthcare Pharmaceuticals
Nifty 500 Smallcap 50 Smallcap 100 Smallcap 250
₹23,535.00
-1.11%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.16.
  • Comfortable interest cover: operating profit covers interest about 24.2 times.
  • Return on equity is healthy at 21.2%.
  • Return on capital employed is healthy at 26.5%.
  • Net profit margin is strong at 18%.
  • Profit has compounded about 39% a year over five years.
  • Sales have compounded about 17% a year over five years.
  • Pays a dividend (yield about 0.14%).
  • Has paid a dividend in each of the last 5 years on record.
  • Promoters hold a sizeable stake (32.62%).

!Watch-points

No notable watch-points flagged by the automated checks.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
8.42

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Computed without the working-capital term (current-asset split not available for this stock).

Piotroski F-ScoreModerate
5 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap₹ 30,195 Cr
Current Price₹ 23,535.00
High / Low₹ 24,225.00 / 11,500.00
Stock P/E60.60567
Book Value₹ 1,461.00
Dividend Yield0%
ROCE26.50%
ROE21.20%
Face Value₹ 10.00
Debt to Equity0.16
PEG Ratio2.02
EV / EBITDA45.38
Industry PE35.70
P/B Ratio16.108608
EPS₹ 283.71
Debt₹ 301 Cr
PAT Margin17.99%
Cash PAT₹ 456 Cr
ICR24.17
Promoter Holding32.62%
FII Holding21.08%
DII Holding16.52%
Public Holding29.79%

Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).

Compounded Sales Growth
10 Years 15.00%
5 Years 17.00%
3 Years 19.00%
TTM 78.00%
Compounded Profit Growth
10 Years 29.00%
5 Years 39.00%
3 Years 30.00%
TTM 278.00%
Stock Price CAGR
10 Years 37.00%
5 Years 69.00%
3 Years 87.00%
1 Year 47.00%
Return on Equity
10 Years 14.00%
5 Years 18.00%
3 Years 20.00%
Last Year 21.00%
Educational data only. Not a recommendation to buy, sell or hold any security.